Call 800 665 0411 to learn about our services for your stock

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS

Share on StockTwits

Telemedicine Co. Surges on Revenue News

Streetwise Reports


November 7, 2022 ( Newswire) As internet-enabled health care becomes more accepted in the wake of the pandemic, telemedicine company Reliq Health Technologies Inc. is seeing its revenue soar.

Shares of telemedicine company Reliq Health Technologies Inc. (RHT:TSX.V; RQHTF:OTCQB; A2AJTB:WKN) went up nearly 20% this week on news that its revenue increased 485% to CA$8.6 million from the fiscal year 2021 to the fiscal year 2022.

Its share price went up from CA$0.52 to CA$0.62 the day the news was released on Wednesday. The day before, technical analyst Clive Maund wrote that the stock was "believed to have been in a basing process since last May."

"It attempted to break higher on increased volume about a week ago, but with its 200-day moving average still dropping toward the price overhead, it was not quite ready," he wrote on Tuesday, saying it was a "good time to buy."

Jefferson Research also raised its rating of the stock from Sell to Hold, saying its earnings quality in the third quarter went from "strong" to "strongest," and its cash flow quality improved from "weak" to "strong."

"Cash flow is considered by many investors to be the ultimate measure of company performance and more reliable than reported earnings," Jefferson wrote.

Huge changes because of the COVID-19 pandemic have contributed to the increasing acceptance of home-based services, Reliq Chief Executive Officer Lisa Crossley told Streetwise Reports.

"COVID helped with getting clinicians who otherwise weren't particularly comfortable with the concept of virtual care and forced them to be comfortable," Crossley said. "That's definitely helped drive adoption for us."

The company said gross profits increased YOY by more than 515% to CA$5.3 million, and the gross margin for the year was 62%.

Revenue for Reliq's software and service sales increased more than 1,940% to CA$2.7 million for the fiscal year 2022, which ended June 30, compared to more than CA$134,000 for the fiscal year 2021.

The company said gross profits increased YOY by more than 515% to CA$5.3 million, and the gross margin for the year was 62%.

The Catalyst

Internet-enabled health care is becoming more accepted in the wake of the pandemic. Government and private insurance plans have expanded their coverage for the services, allowing more doctors to look at remote solutions like Reliq's remote patient monitoring and virtual care platform.

Reliq expects to have as many as 200,000 patients on its platform by the middle of 2023.

"We have a certain number of clients and patients (that have already) announced and committed" to the platform, Crossley said. "But we're also starting to really pick up in terms of the size of contracts that we're signing and the size of clients that we're working with."

Reliq recently signed new contracts, including expanding one with a network of skilled nursing facilities in Florida to add as many as 60,000 new patients per year onto the platform, iUGO. Each patient is expected to generate US$65 per month at a 75% gross margin.

Word of Mouth

Crossley said the company is expecting rapid growth the more contracts it signs with such facilities.

"We've gotten to the point where word of mouth is really driving a lot of our business, but not just with individual physician practices and home health agencies, but with these much larger networks," she said.

Skilled nursing facilities are a largely untapped market for the company. Reliq said there are over 15,000 of them in the United States and more than 1.5 million Medicare patients received care from such networks in 2021.

The average practice can generate new revenue of more than US$400 per patient per month with the platform while paying US$40 to US$100 per patient per month to subscribe to iUGO.

The company also does the pre-screening and pre-authorizations with Medicare and Medicaid and electronic submissions for payment.

Diseases the company aims to manage at home include chronic obstructive pulmonary disease (COPD), congestive heart failure, diabetes, hypertension, and others. Patients get audible reminders to step on a scale, take their blood pressure, or prick their fingers for glucose monitoring. The information is automatically uploaded to the cloud.

Ownership and Share Structure

Top shareholders include Crossley, who owns 1.56% or 3 million shares; Penserra Capital Management LLC, which owns 0.23% or 0.43 million shares; and Eugene Beukman, who owns 0.12% or 0.23 million shares, according to Reuters.

The company has 191.5 million shares outstanding, with 188 million of them free-floating. It has a market cap of CA$128 million and trades in a 52-week range of CA$1.33 and CA$0.36.


1) Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Reliq Health Technologies Inc. Click here for important disclosures about sponsor fees.

3) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

4) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Reliq Health Technologies Inc., a company mentioned in this article.

5) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

More Info: Newswire

This news is published on the Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire

Global investors must adhere to regulations of each country. Please read privacy policy:

That's all it takes to get an article published on Investor Ideas - Learn More - A Leading Global Investor Website for Biotech Industry Stocks - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Buy a biotech guest post on